Skip to content

Instantly share code, notes, and snippets.

@Shawn-Armstrong

Shawn-Armstrong/info.md

Last active January 13, 2024 18:54
Show Gist options
  • Save Shawn-Armstrong/60d77a1e39aa0bfda1cbcc30de101221 to your computer and use it in GitHub Desktop.
Save Shawn-Armstrong/60d77a1e39aa0bfda1cbcc30de101221 to your computer and use it in GitHub Desktop.
Download ZIP
Raw
info.md

Apogee Therapeutics Overview

Company Profile

  • Name: Apogee Therapeutics, Inc.
  • Industry: Biotechnology
  • Founded: 2022
  • IPO Date: July 14, 2023
  • Location: Waltham, Massachusetts, USA
  • CEO: Dr. Michael Thomas Henderson M.D.
  • Website: Apogee Therapeutics

Business Focus

Apogee Therapeutics specializes in developing biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and other inflammatory and immune diseases.

Key Developments

  • APG777 and APG808: Subcutaneous extended half-life monoclonal antibodies for AD and COPD, respectively.
  • APG990 and APG222: Earlier-stage programs for the treatment of AD.

Strategic Information

  • Objective: Reshaping the standard of care for inflammatory and immune diseases.
  • Pipeline: Focus on differentiated antibody therapeutics targeting well-established biological drivers.

Financial Overview (As of Q3 2023)

  • Cash Balance: $422.9 million
  • R&D Expenses: $17.1 million
  • G&A Expenses: $7.2 million
  • Net Loss: $20.8 million

Corporate Developments

  • Expanded board of directors and leadership team, including healthcare veteran Mark C. McKenna as Chairman.
  • Participation in key healthcare conferences and investor events.

For detailed information and updates, visit Apogee Therapeutics Official Website and their latest SEC filings.

Sources:

Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment